Online therapy to help cancer patients find meaning after transplantation

The Effect of an Online Acceptance and Commitment Intervention on Meaning-Making Process in Cancer Patients Following Hematopoietic Cell Transplantation: a Randomized Controlled Trial Enhanced With a Single-case Experimental Design

Not applicable Interventional University of Social Sciences and Humanities, Warsaw · NCT06266182

This study is testing an online therapy program to see if it can help cancer patients who have had a stem cell transplant find meaning in their experiences.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment192 (estimated)
Ages18 Years and up
SexAll
SponsorUniversity of Social Sciences and Humanities, Warsaw Academic / other
Locations1 site (Gliwice)
Trial IDNCT06266182 on ClinicalTrials.gov

What this trial studies

This trial evaluates the effectiveness of an internet-based Acceptance and Commitment Therapy (ACT) intervention aimed at helping cancer patients who have undergone hematopoietic cell transplantation (HCT) to process their experiences and find meaning in their journey. A total of 192 patients will be randomly assigned to either the ACT intervention or an educational session, participating in a 14-day program that requires 5-10 minutes of daily engagement. The study will measure outcomes at various intervals, including baseline, during the intervention, and at one and three months post-intervention, to assess the feasibility and preliminary efficacy of the ACT approach. Additionally, a subset of participants will undergo pre-intervention measurements to enhance the study's design.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older who are undergoing their first autologous or allogeneic hematopoietic cell transplantation for hematologic malignancies or solid tumors.

Not a fit: Patients with major psychiatric or cognitive disorders, those currently in psychotherapy, or individuals lacking internet access will not benefit from this study.

Why it matters

Potential benefit: If successful, this intervention could significantly improve the psychological well-being and meaning-making processes of cancer patients post-transplant.

How similar studies have performed: While the specific application of ACT in this context may be novel, similar interventions have shown promise in improving psychological outcomes for cancer patients in other studies.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Qualification for the first autologous or allogeneic HCT due to hematologic malignancies or solid tumors
* Age ≥ 18 years
* Signed written informed consent
* Ability to read and write in Polish
* Daily access to the Internet by computer and/or mobile device

Exclusion Criteria:

* Major psychiatric or cognitive disorder that would impede providing informed consent and study participation
* Inability to cooperate and give informed consent
* Hearing, seeing, or movement impairment that precludes participation
* Current participation in any form of psychotherapy
* No access to the Internet
* No access to a computer and/or mobile device
* Inability to use a computer and/or mobile device and the Internet

Where this trial is running

Gliwice

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Hematopoietic Cell Transplantation RecipientAcceptance and Commitment Therapycancer patientshematopoietic cell transplantationACT-based interventionweb-based interventionmeaning-makingsubjective well-being
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.